Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8161 to 8175 of 8221 results

  1. World's first gene editing therapy for blood disorder to be available to hundreds of patients in England

    Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.

  2. 14,000 women at risk of fractures after the menopause to benefit from bone disease drug

    Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.

  3. NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

    Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.

  4. More than 40,000 people could benefit after NICE recommends new 'take at home' pill for advanced prostate cancer

    Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.

  5. NICE recommends digital technology to help diagnose ADHD in children and young people

    A digital technology that will help healthcare professionals provide a quicker diagnosis to people with attention deficit hyperactivity disorder (ADHD) can be used by the NHS, NICE has said in draft guidance.

  6. New joint guideline recommends prescribing combination treatments for people with newly diagnosed asthma

    For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.

  7. NICE responds to failure of talks to reach price agreement on Enhertu

    Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.

  8. Towards a new partnership – NICE and the voluntary and community sector

    Victoria Thomas gives details of NICE’s new voluntary and community sector forum.

  9. Keep the size of your waist to less than half of your height, NICE recommends

    People are being encouraged to keep their waist measurement to less than half their height to reduce the risk of potential health problems.

  10. People who have had a stroke should be offered additional rehabilitation

    People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover

  11. Three treatments for COVID-19 recommended in final draft guidance

    Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.

  12. NICE signs up to join the GetReal Institute

    NICE and the GetReal Institute: facilitating the adoption and implementation of real-world evidence in health care decision-making.

  13. Updated guideline recommends more treatment choices for menopause symptoms

    New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).

  14. Thousands of appointments released for the NHS without compromising safety

    Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term

  15. New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer

    Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..